The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials
The Lancet Regional Health - Western Pacific · 2025-02 · 55 · 101492
DOI: 10.1016/j.lanwpc.2025.101492 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Regional Health - Western Pacific, 2025-02. Verfasst von Rebekah M Ahmed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Themen: Demenz
Abstract (Originalsprache)
In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. Often patients in remote and rural regions and those in low income regions are disadvantaged. Many clinical trials for dementia patients are biased to recruiting a homogenous group of patients that does not represent cultural and linguistic diversity, meaning the generalisability of trials is limited. This viewpoint discusses the barriers to access to early treatments and clinical trials for patients with dementia and offers a potential framework to address these including provision of infrastructure, regulatory change and patient education.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia.
- Brain and Mind Centre, University of Sydney, Australia.
- School of Psychology, The University of Sydney, Australia.
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
Förderung
- National Health and Medical Research Council
Zitieren
APA
Ahmed, R. M., Piguet, O., Mummery, C. J., Naismith, S. L., & Irish, M. (2025). The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials. The Lancet Regional Health - Western Pacific, 55, 101492. https://doi.org/10.1016/j.lanwpc.2025.101492
Vancouver
Ahmed RM, Piguet O, Mummery CJ, Naismith SL, Irish M. The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials. The Lancet Regional Health - Western Pacific. 2025;55:101492. doi:10.1016/j.lanwpc.2025.101492
BibTeX
@article{Ahmed2025,
author = {Ahmed, Rebekah M and Piguet, Olivier and Mummery, Catherine J and Naismith, Sharon L and Irish, Muireann},
title = {The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials},
journal = {The Lancet Regional Health - Western Pacific},
year = {2025},
volume = {55},
pages = {101492},
doi = {10.1016/j.lanwpc.2025.101492}
}
EUVIMED